BioPorto Logo

BioPorto

IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.

BIOPOR | CO

Overview

Corporate Details

ISIN(s):
DK0011048619
LEI:
5299004SWFL5JAN4W830
Country:
Denmark
Address:
Tuborg Havnevej 15, st., 2900 Hellerup
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioPorto is an in-vitro diagnostics (IVD) company focused on developing and commercializing actionable biomarkers to improve patient management and outcomes. The company's core technology centers on the NGAL biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI), a condition where traditional diagnostic methods are often delayed and non-specific. Its product portfolio includes The NGAL Test™, which is CE-marked and available internationally, and ProNephro AKI (NGAL), the first FDA-cleared biomarker test for pediatric AKI risk assessment. Additionally, BioPorto provides a range of NGAL ELISA kits for preclinical and clinical research, as well as antibodies for the development of various diagnostic immunoassays.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-15 07:56
Earnings Release
English 738.6 KB
2025-08-15 07:56
Earnings Release
English 17.0 KB
2025-08-15 07:56
Earnings Release
English 738.6 KB
2025-08-15 07:56
Earnings Release
Danish 16.9 KB
2025-06-27 09:19
Regulatory News Service
English 7.4 KB
2025-06-27 09:19
Earnings Release
Danish 7.4 KB
2025-06-10 16:19
Board/Management Information
Danish 8.5 KB
2025-06-10 16:19
Board/Management Information
English 7.9 KB
2025-06-10 16:19
Board/Management Information
English 90.8 KB
2025-06-10 16:19
Board/Management Information
Danish 119.0 KB
2025-04-25 13:55
Director's Dealing
English 28.4 KB
2025-04-25 13:55
Director's Dealing
Danish 155.6 KB
2025-04-25 13:55
Director's Dealing
English 133.6 KB
2025-04-25 13:55
Director's Dealing
Danish 28.7 KB
2025-04-25 13:45
Share Issue/Capital Change
English 84.5 KB

Automate Your Workflow. Get a real-time feed of all BioPorto filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for BioPorto via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan 2927
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX

Talk to a Data Expert

Have a question? We'll get back to you promptly.